Osteopore has inked a three-year distribution agreement with Al-Umnia Medical to bring its 3D-printed orthopaedic implants to five Gulf countries, targeting a rapidly expanding regional market.
- Three-year distribution deal with Al-Umnia covering five GCC countries
- Focus on orthopaedic bone reconstruction products
- GCC orthopaedic devices market forecast to grow to USD 1.55 billion by 2034
- Al-Umnia’s strong regional presence and EUR 10m+ annual sales
- Product registration underway in Saudi Arabia, UAE, Oman, Qatar, Bahrain
Strategic Expansion into High-Growth Middle East Orthopaedic Market
Osteopore Limited (ASX:OSX) is stepping up its international commercialisation drive with a new three-year distribution agreement targeting the Gulf Cooperation Council (GCC) region. The Australian-Singaporean regenerative medicine company has partnered with Dubai-based Al-Umnia Medical LLC to distribute its orthopaedic bone reconstruction products across Saudi Arabia, the United Arab Emirates, Oman, Qatar, and Bahrain.
The deal marks a significant push beyond Osteopore’s established Southeast Asian markets, tapping into a region where orthopaedic demand bucks global trends. Unlike many parts of the world where fracture incidence is stabilising or declining, the Middle East and North Africa have seen a 4.57% rise in lower-extremity fractures from 1990 to 2019. Saudi Arabia notably records the highest fracture rates in the region, driven largely by road trauma among a young, working-age population.
Al-Umnia’s Regional Footprint and Market Opportunity
Founded in 2009 with just four employees, Al-Umnia has grown into a 70-plus strong medical technology distributor with a multi-departmental structure focused on clinical education and support. The company has maintained an annual sales turnover exceeding EUR 10 million since 2023, positioning it as a credible partner for Osteopore’s entry into the GCC orthopaedic devices market.
The GCC market itself was valued at approximately USD 897.5 million in 2025 and is forecast to expand to USD 1.55 billion by 2034, growing at a compound annual growth rate of 6.04%. The UAE holds the lion’s share at 31.5%, making it the largest single market within the region. Synthetic bone substitutes, Osteopore’s specialty, represent a distinct and growing segment within this space.
Next Steps and Commercial Outlook
Osteopore and Al-Umnia will now begin the regulatory process to register Osteopore’s orthopaedic products in each country, navigating local requirements and practices. The agreement includes a termination clause tied to sales performance, underscoring the commercial expectations behind this expansion.
CEO Dr Yujing Lim highlighted the strategic importance of the deal, noting the move as a natural progression in the commercialisation of Osteopore’s orthopaedic product line. She praised Al-Umnia’s strong regional presence and focus on clinical education, which should support product adoption and market penetration.
While the agreement opens the door to a promising growth corridor, the pace of regulatory approvals and initial sales traction will be critical to watch. The partnership follows Osteopore’s recent efforts to broaden its distribution footprint, including deals in Asia and Latin America, as well as incremental funding draws to support its growth ambitions.
Bottom Line?
Osteopore’s Middle East expansion taps into a growing orthopaedic market but hinges on regulatory approvals and sales execution in a competitive region.
Questions in the middle?
- How quickly will Osteopore secure product registrations across the five GCC countries?
- What initial sales volumes and revenue can Osteopore expect from this new partnership?
- How will Osteopore differentiate its synthetic bone substitutes against established competitors in the Middle East?